Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: npguy who wrote (432)	12/23/1997 6:57:00 PM
From: Ken Crooks	Read Replies (1) \| Respond to of 834

Currently, Zacks rates txb a strong buy, #3 of 124 biomed companies; SmartMoney, also a strong buy. Though each only shows 3 analysts rating the stock, I tend to favor the six of them against Wexley. Beyond the Novastan approval, seems that the endothelin antagonist and the asthma med hold the real potential for lofting txb (or not). Wexsley, I'll read one more of your messages IF you will state what the big deal is about visiting the company. Exactly WHAT are you trying to say? Do you mean to say there's nobody there, that they are doing nothing except produce paper? Seems that you may be pushing slander laws on this. I'll be happy to forward your response to txb. Thanks.